Molecular mechanisms of pluripotency and reprogramming

Stem Cell Research and Therapy

Volumn 1, Issue 4, 2010, Pages

  Na, Jie ^a   Plews, Jordan ^b   Li, Jianliang ^b   Wongtrakoongate, Patompon ^b   Tuuri, Timo ^b   Feki, Anis ^c   Andrews, Peter W ^b   Unger, Christian ^b  

^a Tsinghua University   (China)

^b UNIVERSITY OF SHEFFIELD   (United Kingdom)

^c GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

KRUPPEL LIKE FACTOR 4; MICRORNA; MYC PROTEIN; OCTAMER TRANSCRIPTION FACTOR 4; TRANSCRIPTION FACTOR NANOG; TRANSCRIPTION FACTOR SOX2;

CELL CYCLE REGULATION; CELL DIFFERENTIATION; CELL MATURATION; DNA DAMAGE; DNA REPAIR; EMBRYONAL CARCINOMA STEM CELL; EPIGENETICS; GENE EXPRESSION REGULATION; HUMAN; INNER CELL MASS; MOLECULAR MECHANICS; NONHUMAN; PLURIPOTENT STEM CELL; PRIORITY JOURNAL; PROTEIN FUNCTION; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION; SOMATIC CELL; SPECIES DIFFERENCE;

ANIMALS; CELL CYCLE; CELL DIFFERENTIATION; DNA DAMAGE; DNA REPAIR; EMBRYONIC STEM CELLS; GENE EXPRESSION REGULATION; HOMEODOMAIN PROTEINS; HUMANS; MICE; MICRORNAS; NEOPLASTIC STEM CELLS; NUCLEAR REPROGRAMMING; OCTAMER TRANSCRIPTION FACTOR-3; PLURIPOTENT STEM CELLS; SOXB1 TRANSCRIPTION FACTORS;

EID: 80052421188     PISSN: None     EISSN: 17576512     Source Type: Journal    
DOI: 10.1186/scrt33     Document Type: Review

References (103)

1. Spontaneous testicular teratomas in an inbred strain of mice. Stevens LC, Little CC, Proc Natl Acad Sci USA 1954 40 1080 1087 10.1073/pnas.40.11.1080 16578442
2. The biology of teratomas. Stevens LC, Adv Morphog 1967 6 1 31 4894128
3. From teratocarcinomas to embryonic stem cells and beyond: a history of embryonic stem cell research. Solter D, Nat Rev Genet 2006 7 319 327 10.1038/nrg1827 16534514
4. Isolation of a pluripotent cell line from early mouse embryos cultured in medium conditioned by teratocarcinoma stem cells. Martin GR, Proc Natl Acad Sci USA 1981 78 7634 7638 10.1073/pnas.78.12.7634 6950406 (Pubitemid 12186197)
5. Establishment in culture of pluripotential cells from mouse embryos. Evans MJ, Kaufman MH, Nature 1981 292 154 156 10.1038/292154a0 7242681 (Pubitemid 11050741)
6. Normal genetically mosaic mice produced from malignant teratocarcinoma cells. Mintz B, Illmensee K, Proc Natl Acad Sci USA 1975 72 3585 3589 10.1073/pnas.72.9.3585 1059147
7. Formation of pluripotent stem cells in the mammalian embryo depends on the POU transcription factor Oct4. Nichols J, Zevnik B, Anastassiadis K, Niwa H, Klewe-Nebenius D, Chambers I, Scholer H, Smith A, Cell 1998 95 379 391 10.1016/S0092-8674(00)81769-9 9814708 (Pubitemid 28507326)
8. Functional expression cloning of Nanog, a pluripotency sustaining factor in embryonic stem cells. Chambers I, Colby D, Robertson M, Nichols J, Lee S, Tweedie S, Smith A, Cell 2003 113 643 655 10.1016/S0092-8674(03)00392-1 12787505 (Pubitemid 36694189)
9. The homeoprotein Nanog is required for maintenance of pluripotency in mouse epiblast and ES cells. Mitsui K, Tokuzawa Y, Itoh H, Segawa K, Murakami M, Takahashi K, Maruyama M, Maeda M, Yamanaka S, Cell 2003 113 631 642 10.1016/S0092-8674(03)00393-3 12787504 (Pubitemid 36694188)
10. The Hippo signaling pathway components Lats and Yap pattern Tead4 activity to distinguish mouse trophectoderm from inner cell mass. Nishioka N, Inoue K, Adachi K, Kiyonari H, Ota M, Ralston A, Yabuta N, Hirahara S, Stephenson RO, Ogonuki N, Makita R, Kurihara H, Morin-Kensicki EM, Nojima H, Rossant J, Nakao K, Niwa H, Sasaki H, Dev Cell 2009 16 398 410 10.1016/j.devcel.2009.02.003 19289085
11. Transcription factor TEAD4 specifies the trophectoderm lineage at the beginning of mammalian development. Yagi R, Kohn MJ, Karavanova I, Kaneko KJ, Vullhorst D, DePamphilis ML, Buonanno A, Development 2007 134 3827 3836 10.1242/dev.010223 17913785 (Pubitemid 350187342)
12. Cdx2 is required for correct cell fate specification and differentiation of trophectoderm in the mouse blastocyst. Strumpf D, Mao CA, Yamanaka Y, Ralston A, Chawengsaksophak K, Beck F, Rossant J, Development 2005 132 2093 2102 10.1242/dev.01801 15788452 (Pubitemid 40744469)
13. Interaction between Oct3/4 and Cdx2 determines trophectoderm differentiation. Niwa H, Toyooka Y, Shimosato D, Strumpf D, Takahashi K, Yagi R, Rossant J, Cell 2005 123 917 929 10.1016/j.cell.2005.08.040 16325584 (Pubitemid 41721036)
14. Inner cell mass localization of NANOG precedes OCT3/4 in rhesus monkey blastocysts. Harvey AJ, Armant DR, Bavister BD, Nichols SM, Brenner CA, Stem Cells Dev 2009 18 1451 1458 10.1089/scd.2009.0122 19537945
15. Embryonic stem cell lines derived from human blastocysts. Thomson JA, Itskovitz-Eldor J, Shapiro SS, Waknitz MA, Swiergiel JJ, Marshall VS, Jones JM, Science 1998 282 1145 1147 10.1126/science.282.5391.1145 9804556 (Pubitemid 28516247)
16. A comparative study of eight cell lines derived from human testicular teratocarcinoma. Andrews PW, Bronson DL, Benham F, Strickland S, Knowles BB, Int J Cancer 1980 26 269 280 10.1002/ijc.2910260304 6169654 (Pubitemid 10049395)
17. Cellsurface antigens of a clonal human embryonal carcinoma cell line: morphological and antigenic differentiation in culture. Andrews PW, Goodfellow PN, Shevinsky LH, Bronson DL, Knowles BB, Int J Cancer 1982 29 523 531 10.1002/ijc.2910290507 7095898 (Pubitemid 12114626)
18. Comparative analysis of cell surface antigens expressed by cell lines derived from human germ cell tumours. Andrews PW, Casper J, Damjanov I, Duggan-Keen M, Giwercman A, Hata J, von Keitz A, Looijenga LH, Millán JL, Oosterhuis JW, Pera M, Sawada M, Schmoll HJ, Skakkebaek NE, van Putten W, Stern P, Int J Cancer 1996 66 806 816 10.1002/(SICI)1097-0215(19960611)66:6<806:: AID-IJC17>3.0.CO;2-0 8647654 (Pubitemid 26197951)
19. Stage-specific embryonic antigens (SSEA-3 and -4) are epitopes of a unique globo-series ganglioside isolated from human teratocarcinoma cells. Kannagi R, Cochran NA, Ishigami F, Hakomori S, Andrews PW, Knowles BB, Solter D, EMBO J 1983 2 2355 2361 6141938
20. Characterization of human embryonic stem cell lines by the International Stem Cell Initiative. International Stem Cell Initiative, Adewumi O, Aflatoonian B, Ahrlund-Richter L, Amit M, Andrews PW, Beighton G, Bello PA, Benvenisty N, Berry LS, Bevan S, Blum B, Brooking J, Chen KG, Choo AB, Churchill GA, Corbel M, Damjanov I, Draper JS, Dvorak P, Emanuelsson K, Fleck RA, Ford A, Gertow K, Gertsenstein M, Gokhale PJ, Hamilton RS, Hampl A, Healy LE, Hovatta O, et al. Nat Biotechnol 2007 25 803 816 10.1038/nbt1318 17572666 (Pubitemid 47052190)
21. Preimplantation human embryos and embryonic stem cells show comparable expression of stage-specific embryonic antigens. Henderson JK, Draper JS, Baillie HS, Fishel S, Thomson JA, Moore H, Andrews PW, Stem Cells 2002 20 329 337 10.1634/stemcells.20-4-329 12110702 (Pubitemid 34765092)
22. New cell lines from mouse epiblast share defining features with human embryonic stem cells. Tesar PJ, Chenoweth JG, Brook FA, Davies TJ, Evans EP, Mack DL, Gardner RL, McKay RD, Nature 2007 448 196 199 10.1038/nature05972 17597760 (Pubitemid 47067378)
23. Derivation of pluripotent epiblast stem cells from mammalian embryos. Brons IG, Smithers LE, Trotter MW, Rugg-Gunn P, Sun B, Chuva de Sousa Lopes SM, Howlett SK, Clarkson A, Ahrlund-Richter L, Pedersen RA, Vallier L, Nature 2007 448 191 195 10.1038/nature05950 17597762 (Pubitemid 47067373)
24. The growth factor environment defines distinct pluripotent ground states in novel blastocyst-derived stem cells. Chou YF, Chen HH, Eijpe M, Yabuuchi A, Chenoweth JG, Tesar P, Lu J, McKay RD, Geijsen N, Cell 2008 135 449 461 10.1016/j.cell.2008.08.035 18984157
25. Human embryonic stem cells with biological and epigenetic characteristics similar to those of mouse ESCs. Hanna J, Cheng AW, Saha K, Kim J, Lengner CJ, Soldner F, Cassady JP, Muffat J, Carey BW, Jaenisch R, Proc Natl Acad Sci USA 2010 107 9222 9227 10.1073/pnas.1004584107 20442331
26. Derivation of Pre-X inactivation human embryonic stem cells under physiological oxygen concentrations. Lengner CJ, Gimelbrant AA, Erwin JA, Cheng AW, Guenther MG, Welstead GG, Alagappan R, Frampton GM, Xu P, Muffat J, Santagata S, Powers D, Barrett CB, Young RA, Lee JT, Jaenisch R, Mitalipova M, Cell 2010 141 872 883 10.1016/j.cell.2010.04.010 20471072
27. From nuclear transfer to nuclear reprogramming: the reversal of cell differentiation. Gurdon JB, Annu Rev Cell Dev Biol 2006 22 1 22 10.1146/annurev.cellbio.22.090805.140144 16704337
28. Transplantation of living nuclei from blastula cells into enucleated frogs' eggs. Briggs R, King TJ, Proc Natl Acad Sci USA 1952 38 455 463 10.1073/pnas.38.5.455 16589125
29. "Fertile" intestine nuclei. Gurdon JB, Uehlinger V, Nature 1966 210 1240 1241 10.1038/2101240a0 5967799
30. Viable offspring derived from fetal and adult mammalian cells. Wilmut I, Schnieke AE, McWhir J, Kind AJ, Campbell KH, Nature 1997 385 810 813 10.1038/385810a0 9039911 (Pubitemid 27106068)
31. Nuclear transplantation: lessons from frogs and mice. Hochedlinger K, Jaenisch R, Curr Opin Cell Biol 2002 14 741 748 10.1016/S0955-0674(02)00380-0 12473349 (Pubitemid 35449388)
32. Nuclear reprogramming of somatic cells after fusion with human embryonic stem cells. Cowan CA, Atienza J, Melton DA, Eggan K, Science 2005 309 1369 1373 10.1126/science.1116447 16123299 (Pubitemid 41209363)
33. Induction of dedifferentiation, genomewide transcriptional programming, and epigenetic reprogramming by extracts of carcinoma and embryonic stem cells. Taranger CK, Noer A, Sorensen AL, Hakelien AM, Boquest AC, Collas P, Mol Biol Cell 2005 16 5719 5735 10.1091/mbc.E05-06-0572 16195347 (Pubitemid 41752221)
34. Expression of a single transfected cDNA converts fibroblasts to myoblasts. Davis RL, Weintraub H, Lassar AB, Cell 1987 51 987 1000 10.1016/0092-8674(87)90585-X 3690668
35. Stepwise reprogramming of B cells into macrophages. Xie H, Ye M, Feng R, Graf T, Cell 2004 117 663 676 10.1016/S0092-8674(04)00419-2 15163413 (Pubitemid 38692531)
36. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Takahashi K, Yamanaka S, Cell 2006 126 663 676 10.1016/j.cell.2006.07.024 16904174 (Pubitemid 44233629)
37. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, Tomoda K, Yamanaka S, Cell 2007 131 861 872 10.1016/j.cell.2007.11.019 18035408 (Pubitemid 350138099)
38. Induced pluripotent stem cell lines derived from human somatic cells. Yu J, Vodyanik MA, Smuga-Otto K, Antosiewicz-Bourget J, Frane JL, Tian S, Nie J, Jonsdottir GA, Ruotti V, Stewart R, Slukvin II, Thomson JA, Science 2007 318 1917 1920 10.1126/science.1151526 18029452
39. Live cell imaging distinguishes bona fide human iPS cells from partially reprogrammed cells. Chan EM, Ratanasirintrawoot S, Park IH, Manos PD, Loh YH, Huo H, Miller JD, Hartung O, Rho J, Ince TA, Daley GQ, Schlaeger TM, Nat Biotechnol 2009 27 1033 1037 10.1038/nbt.1580 19826408
40. Human induced pluripotent stem cells free of vector and transgene sequences. Yu J, Hu K, Smuga-Otto K, Tian S, Stewart R, Thomson JA, Science 2009 324 797 801 10.1126/science.1172482 19325077
41. A nonviral minicircle vector for deriving human iPS cells. Jia F, Wilson KD, Sun N, Gupta DM, Huang M, Li Z, Panetta NJ, Chen ZY, Robbins RC, Kay MA, Longaker MT, Wu JC, Nat Methods 2010 7 197 199 10.1038/nmeth.1426 20139967
42. Virus-free induction of pluripotency and subsequent excision of reprogramming factors. Kaji K, Norrby K, Paca A, Mileikovsky M, Mohseni P, Woltjen K, Nature 2009 458 771 775 10.1038/nature07864 19252477
43. piggyBac transposition reprograms fibroblasts to induced pluripotent stem cells. Woltjen K, Michael IP, Mohseni P, Desai R, Mileikovsky M, Hämäläinen R, Cowling R, Wang W, Liu P, Gertsenstein M, Kaji K, Sung HK, Nagy A, Nature 2009 458 766 770 10.1038/nature07863 19252478
44. Generation of human induced pluripotent stem cells by direct delivery of reprogramming proteins. Kim D, Kim CH, Moon JI, Chung YG, Chang MY, Han BS, Ko S, Yang E, Cha KY, Lanza R, Kim KS, Cell Stem Cell 2009 4 472 476 10.1016/j.stem.2009.05.005 19481515
45. Generation of induced pluripotent stem cells using recombinant proteins. Zhou H, Wu S, Joo JY, Zhu S, Han DW, Lin T, Trauger S, Bien G, Yao S, Zhu Y, Siuzdak G, Schöler HR, Duan L, Ding S, Cell Stem Cell 2009 4 381 384 10.1016/j.stem.2009.04.005 19398399
46. Induction of pluripotent stem cells from adult somatic cells by protein-based reprogramming without genetic manipulation. Cho HJ, Lee CS, Kwon YW, Paek JS, Lee SH, Hur J, Lee EJ, Roh TY, Chu IS, Leem SH, Kim Y, Kang HJ, Park YB, Kim HS, Blood 2010 116 386 395 10.1182/blood-2010-02-269589 20439621
47. The nuclear receptor Nr5a2 can replace Oct4 in the reprogramming of murine somatic cells to pluripotent cells. Heng JC, Feng B, Han J, Jiang J, Kraus P, Ng JH, Orlov YL, Huss M, Yang L, Lufkin T, Lim B, Ng HH, Cell Stem Cell 2010 6 167 174 10.1016/j.stem.2009.12.009 20096661
48. An expanded Oct4 interaction network: implications for stem cell biology, development, and disease. Pardo M, Lang B, Yu L, Prosser H, Bradley A, Babu MM, Choudhary J, Cell Stem Cell 2010 6 382 395 10.1016/j.stem.2010.03.004 20362542
49. Developmental reprogramming after chromosome transfer into mitotic mouse zygotes. Egli D, Rosains J, Birkhoff G, Eggan K, Nature 2007 447 679 685 10.1038/nature05879 17554301 (Pubitemid 46889733)
50. Direct reprogramming of human neural stem cells by OCT4. Kim JB, Greber B, Arauzo-Bravo MJ, Meyer J, Park KI, Zaehres H, Scholer HR, Nature 2009 461 649 643 10.1038/nature08436 19718018
51. Sox2 is dispensable for the reprogramming of melanocytes and melanoma cells into induced pluripotent stem cells. Utikal J, Maherali N, Kulalert W, Hochedlinger K, J Cell Sci 2009 122 3502 3510 10.1242/jcs.054783 19723802
52. Pluripotency governed by Sox2 via regulation of Oct3/4 expression in mouse embryonic stem cells. Masui S, Nakatake Y, Toyooka Y, Shimosato D, Yagi R, Takahashi K, Okochi H, Okuda A, Matoba R, Sharov AA, Ko MS, Niwa H, Nat Cell Biol 2007 9 625 635 10.1038/ncb1589 17515932 (Pubitemid 47214724)
53. Tgfbeta signal inhibition cooperates in the induction of iPSCs and replaces Sox2 and cMyc. Maherali N, Hochedlinger K, Curr Biol 2009 19 1718 1723 10.1016/j.cub.2009.08.025 19765992
54. A small-molecule inhibitor of tgf-Beta signaling replaces sox2 in reprogramming by inducing nanog. Ichida JK, Blanchard J, Lam K, Son EY, Chung JE, Egli D, Loh KM, Carter AC, Di Giorgio FP, Koszka K, Huangfu D, Akutsu H, Liu DR, Rubin LL, Eggan K, Cell Stem Cell 2009 5 491 503 10.1016/j.stem.2009.09.012 19818703
55. Klf4 cooperates with Oct3/4 and Sox2 to activate the Lefty1 core promoter in embryonic stem cells. Nakatake Y, Fukui N, Iwamatsu Y, Masui S, Takahashi K, Yagi R, Yagi K, Miyazaki J, Matoba R, Ko MS, Niwa H, Mol Cell Biol 2006 26 7772 7782 10.1128/MCB.00468-06 16954384 (Pubitemid 44547722)
56. A parallel circuit of LIF signalling pathways maintains pluripotency of mouse ES cells. Niwa H, Ogawa K, Shimosato D, Adachi K, Nature 2009 460 118 122 10.1038/nature08113 19571885
57. An extended transcriptional network for pluripotency of embryonic stem cells. Kim J, Chu J, Shen X, Wang J, Orkin SH, Cell 2008 132 1049 1061 10.1016/j.cell.2008.02.039 18358816 (Pubitemid 351381745)
58. Klf4 reverts developmentally programmed restriction of ground state pluripotency. Guo G, Yang J, Nichols J, Hall JS, Eyres I, Mansfield W, Smith A, Development 2009 136 1063 1069 10.1242/dev.030957 19224983
59. Generation of induced pluripotent stem cells without Myc from mouse and human fibroblasts. Nakagawa M, Koyanagi M, Tanabe K, Takahashi K, Ichisaka T, Aoi T, Okita K, Mochiduki Y, Takizawa N, Yamanaka S, Nat Biotechnol 2008 26 101 106 10.1038/nbt1374 18059259
60. Embryonic stem cell-specific microRNAs promote induced pluripotency. Judson RL, Babiarz JE, Venere M, Blelloch R, Nat Biotechnol 2009 27 459 461 10.1038/nbt.1535 19363475
61. Myc-regulated microRNAs attenuate embryonic stem cell differentiation. Lin CH, Jackson AL, Guo J, Linsley PS, Eisenman RN, EMBO J 2009 28 3157 3170 10.1038/emboj.2009.254 19745813
62. Myc's other life: stem cells and beyond. Laurenti E, Wilson A, Trumpp A, Curr Opin Cell Biol 2009 21 844 854 10.1016/j.ceb.2009.09.006 19836223
63. Nanog safeguards pluripotency and mediates germline development. Chambers I, Silva J, Colby D, Nichols J, Nijmeijer B, Robertson M, Vrana J, Jones K, Grotewold L, Smith A, Nature 2007 450 1230 1234 10.1038/nature06403 18097409
64. Direct cell reprogramming is a stochastic process amenable to acceleration. Hanna J, Saha K, Pando B, van Zon J, Lengner CJ, Creyghton MP, van Oudenaarden A, Jaenisch R, Nature 2009 462 595 601 10.1038/nature08592 19898493
65. Lin28 recruits the TUTase Zcchc11 to inhibit let-7 maturation in mouse embryonic stem cells. Hagan JP, Piskounova E, Gregory RI, Nat Struct Mol Biol 2009 16 1021 1025 10.1038/nsmb.1676 19713958
66. Stoichiometric and temporal requirements of Oct4, Sox2, Klf4, and c-Myc expression for efficient human iPSC induction and differentiation. Papapetrou EP, Tomishima MJ, Chambers SM, Mica Y, Reed E, Menon J, Tabar V, Mo Q, Studer L, Sadelain M, Proc Natl Acad Sci USA 2009 106 12759 12764 10.1073/pnas.0904825106 19549847
67. A mesenchymal-to-epithelial transition initiates and is required for the nuclear reprogramming of mouse fibroblasts. Li R, Liang J, Ni S, Zhou T, Qing X, Li H, He W, Chen J, Li F, Zhuang Q, Qin B, Xu J, Li W, Yang J, Gan Y, Qin D, Feng S, Song H, Yang D, Zhang B, Zeng L, Lai L, Esteban MA, Pei D, Cell Stem Cell 2010 7 51 63 10.1016/j.stem.2010.04.014 20621050
68. Functional genomics reveals a BMP-driven mesenchymal-to-epithelial transition in the initiation of somatic cell reprogramming. Samavarchi-Tehrani P, Golipour A, David L, Sung H, Beyer TA, Datti A, Woltjen K, Nagy A, Wrana JL, Cell Stem Cell 2010 7 64 77 10.1016/j.stem.2010.04.015 20621051
69. A bivalent chromatin structure marks key developmental genes in embryonic stem cells. Bernstein BE, Mikkelsen TS, Xie X, Kamal M, Huebert DJ, Cuff J, Fry B, Meissner A, Wernig M, Plath K, Jaenisch R, Wagschal A, Feil R, Schreiber SL, Lander ES, Cell 2006 125 315 326 10.1016/j.cell.2006.02.041 16630819
70. Dissecting direct reprogramming through integrative genomic analysis. Mikkelsen TS, Hanna J, Zhang X, Ku M, Wernig M, Schorderet P, Bernstein BE, Jaenisch R, Lander ES, Meissner A, Nature 2008 454 49 55 10.1038/nature07056 18509334 (Pubitemid 351931978)
71. Defined factors induce reprogramming of gastrointestinal cancer cells. Miyoshi N, Ishii H, Nagai K, Hoshino H, Mimori K, Tanaka F, Nagano H, Sekimoto M, Doki Y, Mori M, Proc Natl Acad Sci USA 2010 107 40 45 10.1073/pnas.0912407107 20018687
72. Generation of pluripotent stem cells from adult mouse liver and stomach cells. Aoi T, Yae K, Nakagawa M, Ichisaka T, Okita K, Takahashi K, Chiba T, Yamanaka S, Science 2008 321 699 702 10.1126/science.1154884 18276851
73. Efficient and rapid generation of induced pluripotent stem cells from human keratinocytes. Aasen T, Raya A, Barrero MJ, Garreta E, Consiglio A, Gonzalez F, Vassena R, Bili J, Pekarik V, Tiscornia G, Edel M, Boué S, Izpisúa Belmonte JC, Nat Biotechnol 2008 26 1276 1284 10.1038/nbt.1503 18931654
74. Differentiation stage determines potential of hematopoietic cells for reprogramming into induced pluripotent stem cells. Eminli S, Foudi A, Stadtfeld M, Maherali N, Ahfeldt T, Mostoslavsky G, Hock H, Hochedlinger K, Nat Genet 2009 41 968 976 10.1038/ng.428 19668214
75. Induction of pluripotent stem cells by defined factors is greatly improved by small-molecule compounds. Huangfu D, Maehr R, Guo W, Eijkelenboom A, Snitow M, Chen AE, Melton DA, Nat Biotechnol 2008 26 795 797 10.1038/nbt1418 18568017 (Pubitemid 351961456)
76. A combined chemical and genetic approach for the generation of induced pluripotent stem cells. Shi Y, Do JT, Desponts C, Hahm HS, Scholer HR, Ding S, Cell Stem Cell 2008 2 525 528 10.1016/j.stem.2008.05.011 18522845 (Pubitemid 351729222)
77. Epigenetic memory in induced pluripotent stem cells. Kim K, Doi A, Wen B, Ng K, Zhao R, Cahan P, Kim J, Aryee MJ, Ji H, Ehrlich LI, Yabuuchi A, Takeuchi A, Cunniff KC, Hongguang H, McKinney-Freeman S, Naveiras O, Yoon TJ, Irizarry RA, Jung N, Seita J, Hanna J, Murakami P, Jaenisch R, Weissleder R, Orkin SH, Weissman IL, Feinberg AP, Daley GQ, Nature 2010
78. Cell type of origin influences the molecular and functional properties of mouse induced pluripotent stem cells. Polo JM, Liu S, Figueroa ME, Kulalert W, Eminli S, Tan KY, Apostolou E, Stadtfeld M, Li Y, Shioda T, Natesan S, Wagers AJ, Melnick A, Evans T, Hochedlinger K, Nat Biotechnol 2010 28 848 855 10.1038/nbt.1667 20644536
79. Aberrant silencing of imprinted genes on chromosome 12qF1 in mouse induced pluripotent stem cells. Stadtfeld M, Apostolou E, Akutsu H, Fukuda A, Follett P, Natesan S, Kono T, Shioda T, Hochedlinger K, Nature 2010 465 175 181 10.1038/nature09017 20418860
80. Activation of the imprinted Dlk1-Dio3 region correlates with pluripotency levels of mouse stem cells. Liu L, Luo GZ, Yang W, Zhao X, Zheng Q, Lv Z, Li W, Wu HJ, Wang L, Wang XJ, Zhou Q, J Biol Chem 2010 285 19483 19490 10.1074/jbc.M110.131995 20382743
81. Tbx3 improves the germ-line competency of induced pluripotent stem cells. Han J, Yuan P, Yang H, Zhang J, Soh BS, Li P, Lim SL, Cao S, Tay J, Orlov YL, Lufkin T, Ng HH, Tam WL, Lim B, Nature 2010 463 1096 1100 10.1038/nature08735 20139965
82. Clone-and gene-specific aberrations of parental imprinting in human induced pluripotent stem cells. Pick M, Stelzer Y, Bar-Nur O, Mayshar Y, Eden A, Benvenisty N, Stem Cells 2009 27 2686 2690 10.1002/stem.205 19711451
83. Differential modeling of fragile X syndrome by human embryonic stem cells and induced pluripotent stem cells. Urbach A, Bar-Nur O, Daley GQ, Benvenisty N, Cell Stem Cell 2010 6 407 411 10.1016/j.stem.2010.04.005 20452313
84. Small non-coding RNAs in animal development. Stefani G, Slack FJ, Nat Rev Mol Cell Biol 2008 9 219 230 10.1038/nrm2347 18270516 (Pubitemid 351301826)
85. The let-7 family of microRNAs. Roush S, Slack FJ, Trends Cell Biol 2008 18 505 516 10.1016/j.tcb.2008.07.007 18774294
86. Lin28 mediates the terminal uridylation of let-7 precursor MicroRNA. Heo I, Joo C, Cho J, Ha M, Han J, Kim VN, Mol Cell 2008 32 276 284 10.1016/j.molcel.2008.09.014 18951094
87. Selective blockade of microRNA processing by Lin28. Viswanathan SR, Daley GQ, Gregory RI, Science 2008 320 97 100 10.1126/science.1154040 18292307 (Pubitemid 351490762)
88. Two supporting factors greatly improve the efficiency of human iPSC generation. Zhao Y, Yin X, Qin H, Zhu F, Liu H, Yang W, Zhang Q, Xiang C, Hou P, Song Z, Liu Y, Yong J, Zhang P, Cai J, Liu M, Li H, Li Y, Qu X, Cui K, Zhang W, Xiang T, Wu Y, Zhao Y, Liu C, Yu C, Yuan K, Lou J, Ding M, Deng H, Cell Stem Cell 2008 3 475 479 10.1016/j.stem.2008.10.002 18983962
89. Senescence impairs successful reprogramming to pluripotent stem cells. Banito A, Rashid ST, Acosta JC, Li S, Pereira CF, Geti I, Pinho S, Silva JC, Azuara V, Walsh M, Vallier L, Gil J, Genes Dev 2009 23 2134 2139 10.1101/gad.1811609 19696146
90. Immortalization eliminates a roadblock during cellular reprogramming into iPS cells. Utikal J, Polo JM, Stadtfeld M, Maherali N, Kulalert W, Walsh RM, Khalil A, Rheinwald JG, Hochedlinger K, Nature 2009 460 1145 1148 10.1038/nature08285 19668190
91. The Ink4/Arf locus is a barrier for iPS cell reprogramming. Li H, Collado M, Villasante A, Strati K, Ortega S, Canamero M, Blasco MA, Serrano M, Nature 2009 460 1136 1139 10.1038/nature08290 19668188
92. A p53-mediated DNA damage response limits reprogramming to ensure iPS cell genomic integrity. Marion RM, Strati K, Li H, Murga M, Blanco R, Ortega S, Fernandez-Capetillo O, Serrano M, Blasco MA, Nature 2009 460 1149 1153 10.1038/nature08287 19668189
93. Suppression of induced pluripotent stem cell generation by the p53-p21 pathway. Hong H, Takahashi K, Ichisaka T, Aoi T, Kanagawa O, Nakagawa M, Okita K, Yamanaka S, Nature 2009 460 1132 1135 10.1038/nature08235 19668191
94. Linking the p53 tumour suppressor pathway to somatic cell reprogramming. Kawamura T, Suzuki J, Wang YV, Menendez S, Morera LB, Raya A, Wahl GM, Belmonte JC, Nature 2009 460 1140 1144 10.1038/nature08311 19668186
95. Vitamin C enhances the generation of mouse and human induced pluripotent stem cells. Esteban MA, Wang T, Qin B, Yang J, Qin D, Cai J, Li W, Weng Z, Chen J, Ni S, Chen K, Li Y, Liu X, Xu J, Zhang S, Li F, He W, Labuda K, Song Y, Peterbauer A, Wolbank S, Redl H, Zhong M, Cai D, Zeng L, Pei D, Cell Stem Cell 2009 6 71 79 10.1016/j.stem.2009.12.001 20036631
96. SV40 large T-antigen disturbs the formation of nuclear DNA-repair foci containing MRE11. Digweed M, Demuth I, Rothe S, Scholz R, Jordan A, Grotzinger C, Schindler D, Grompe M, Sperling K, Oncogene 2002 21 4873 4878 10.1038/sj.onc.1205616 12118365
97. Improved efficiency and pace of generating induced pluripotent stem cells from human adult and fetal fibroblasts. Mali P, Ye Z, Hommond HH, Yu X, Lin J, Chen G, Zou J, Cheng L, Stem Cells 2008 26 1998 2005 10.1634/stemcells.2008-0346 18511599
98. Induced pluripotent stem cells and embryonic stem cells are distinguished by gene expression signatures. Chin MH, Mason MJ, Xie W, Volinia S, Singer M, Peterson C, Ambartsumyan G, Aimiuwu O, Richter L, Zhang J, Khvorostov I, Ott V, Grunstein M, Lavon N, Benvenisty N, Croce CM, Clark AT, Baxter T, Pyle AD, Teitell MA, Pelegrini M, Plath K, Lowry WE, Cell Stem Cell 2009 5 111 123 10.1016/j.stem.2009.06.008 19570518
99. Differential methylation of tissue-and cancer-specific CpG island shores distinguishes human induced pluripotent stem cells, embryonic stem cells and fibroblasts. Doi A, Park IH, Wen B, Murakami P, Aryee MJ, Irizarry R, Herb B, Ladd-Acosta C, Rho J, Loewer S, Miller J, Schlaeger T, Daley GQ, Feinberg AP, Nat Genet 2009 41 1350 1353 10.1038/ng.471 19881528
100. Hemangioblastic derivatives from human induced pluripotent stem cells exhibit limited expansion and early senescence. Feng Q, Lu SJ, Klimanskaya I, Gomes I, Kim D, Chung Y, Honig GR, Kim KS, Lanza R, Stem Cells 2010 28 704 712 10.1002/stem.321 20155819
101. Good manufacturing practice and clinical-grade human embryonic stem cell lines. Unger C, Skottman H, Blomberg P, Dilber MS, Hovatta O, Hum Mol Genet 2008 17 48 53 10.1093/hmg/ddn079 18632697
102. Prospects for stem cell-based therapy. Daley GQ, Scadden DT, Cell 2008 132 544 548 10.1016/j.cell.2008.02.009 18295571 (Pubitemid 351253699)
103. Progress toward the clinical application of patient-specific pluripotent stem cells. Kiskinis E, Eggan K, J Clin Invest 2010 120 51 59 10.1172/JCI40553 20051636